Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib cardiac safety in advanced solid malignancies
NCT04865159Phase 1Terminated
- Sponsor
- Kura Oncology
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tipifarnib in solid tumor (advanced stage), sponsored by Kura Oncology. Primary endpoint: Change from baseline in time-matched difference in QTc interval at 7 days. Started May 2021; status: terminated.
02
Drugs
tipifarnib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04865159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865159.